Showing results (1-10 of 56) with videos related to
Sort By:
Pageof 6
Internal and Emergency Medicine|October 20, 2011
What intervention trials don't tell us: the residual risk in primary preventionClaudio CimminielloGiornale Italiano Di Cardiologia (2006)|June 18, 2016
[The new lipid-lowering drugs: focus on monoclonal antibodies]Claudio Borghi, Claudio CimminielloThrombosis Journal|February 20, 2014
Warfarin and atrial fibrillation: from ideal to real the warfarin affaireMauro Molteni, Claudio CimminielloThrombosis Research|August 6, 2011
Physician and patient perceptions of the route of administration of venous thromboembolism prophylaxis: results from an international surveyClaudio Cimminiello, Frederick A AndersonThrombosis Journal|September 9, 2015
The dogma of aspirin: a critical review of evidence on the best monotherapy after dual antiplatelet therapyHernan Polo Friz, Mauro Molteni, Claudio CimminielloGiornale Italiano Di Cardiologia (2006)|June 18, 2016
[Hypercholesterolemia and cardiovascular risk: advantages and limitations of current treatment options]Claudio Cimminiello, Alberto Zambon, Hernan Polo FrizCoronary Artery Disease|July 9, 2025
Why colchicine is not beneficial in patients with acute coronary syndrome? In search of a CLEAR answerStefano De Servi, Mauro Molteni, Claudio CimminielloCardiovascular Therapeutics|April 15, 2020
The Role of Clopidogrel in 2020: A ReappraisalGiuseppe Patti, Giuseppe Micieli, Claudio Cimminiello, et al.European Journal of Internal Medicine|June 7, 2025
Long-term secondary prevention with colchicine in patients with CAD: an updated systematic review and meta-analysisPatrizia Boracchi, Giuseppe Marano, Ester Luconi, et al.Thrombosis Journal|May 12, 2017
The introduction of biosimilars of low molecular weight heparins in Europe: a critical review and reappraisal endorsed by the Italian Society for Haemostasis and Thrombosis (SISET) and the Italian Society for Angiology and Vascular Medicine (SIAPAV)Davide Imberti, Marco Marietta, Hernan Polo Friz, et al.Pageof 6